SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Venus Concept Inc. (VERO) (CIK 0001409269) (VERO) — Feb 6, 2020

Venus Concept Inc. (VERO) (CIK 0001409269)
Date: Feb. 6, 2020 · CIK: 0001409269 · Accession: 0000000000-20-001184

AI Filing Summary & Sentiment

File numbers found in text: 333-236207

Date
February 6, 2020
Author
Not clearly detected
Form
UPLOAD
Company
Venus Concept Inc. (VERO) (CIK 0001409269)

Letter

February 6, 2020 Domenic Serafino Chief Executive Officer Venus Concept Inc. 235 Yorkland Blvd, Suite 900 Toronto, Ontario M2J 4Y8 Re:Venus Concept Inc. Registration Statement on Form S-3 Filed January 31, 2020 File No. 333-236207 Dear Mr. Serafino: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Danielle Carbone, Esq.

Show Raw Text
February 6, 2020
Domenic Serafino
Chief Executive Officer
Venus Concept Inc.
235 Yorkland Blvd, Suite 900
Toronto, Ontario M2J 4Y8
Re:Venus Concept Inc.
Registration Statement on Form S-3
Filed January 31, 2020
File No. 333-236207
Dear Mr. Serafino:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Danielle Carbone, Esq.